Sonepcizumab shows promise for metastatic kidney cancer
Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). [...]